What are the contraindications to using Retacrit (epoetin alfa) in a postoperative patient after cardiothoracic surgery?

Retacrit Use After Cardiothoracic Surgery: Critical Contraindications and Warnings

Retacrit (epoetin alfa) carries significant contraindications and serious warnings for postoperative cardiothoracic surgery patients, most notably uncontrolled hypertension as an absolute contraindication, and critically, FDA warnings specifically identify increased mortality and thromboembolism risk in patients undergoing coronary artery bypass graft (CABG) surgery. 1

Absolute Contraindications

The FDA label for Retacrit explicitly lists the following as contraindications 1:

• Uncontrolled hypertension - This is particularly relevant post-cardiac surgery when blood pressure management is critical
• Pure red cell aplasia (PRCA) that developed after treatment with epoetin alfa or other erythropoietin products
• Serious allergic reactions to Retacrit or other epoetin alfa products
• Multiple-dose vials containing benzyl alcohol are contraindicated in neonates, infants, pregnant women, and lactating women

Critical Black Box Warnings for Cardiac Surgery Patients

The FDA label contains explicit warnings about increased risk of death and deep venous thrombosis (DVT) in patients undergoing CABG surgery 1. This is not merely a theoretical concern - controlled clinical trials demonstrated:

• Increased mortality risk when ESAs are used in cardiac surgery patients
• Increased risk of deep venous thrombosis in surgical patients
• Increased risk of myocardial infarction, stroke, and thromboembolism across multiple patient populations

The label specifically states: "In controlled clinical trials, ESAs increased the risk of death in patients undergoing coronary artery bypass graft surgery (CABG) and the risk of deep venous thrombosis (DVT) in patients undergoing orthopedic procedures." 1

Clinical Evidence Supporting Caution

A case report documented periprocedural myocardial infarction and early saphenous vein graft occlusion in a patient given epoetin alfa before CABG surgery, with the authors concluding that "epogen administration can cause myocardial infarction and coronary artery thrombosis" and recommending "very cautious" use in patients with underlying coronary artery disease 2.

Additionally, research showed that two large preoperative doses of erythropoietin may actually augment the inflammatory response to cardiac surgery, increasing TNF-alpha and NT-proBNP levels rather than providing anti-inflammatory benefit 3.

When Retacrit May Be Considered (With Extreme Caution)

The FDA label does include a specific dosing regimen for surgery patients 1:

• 300 Units/kg/day subcutaneously for 15 days total (10 days before, day of, and 4 days after surgery), OR
• 600 Units/kg subcutaneously in 4 doses (21,14, and 7 days before surgery and on day of surgery)

However, the label mandates that "deep venous thrombosis prophylaxis is recommended during RETACRIT therapy" 1.

Clinical Decision Algorithm

For postoperative cardiothoracic surgery patients:

1. Screen for absolute contraindications first:

   • Check blood pressure control - if uncontrolled hypertension present, Retacrit is absolutely contraindicated
   • Review history for prior PRCA or serious allergic reactions to epoetin products

2. Assess thrombotic risk:

   • Recent CABG surgery = very high risk - the FDA specifically warns against use in this population
   • Consider that the patient has just undergone a procedure with inherently high thrombotic risk
   • Evaluate for any signs of early graft complications or thrombosis

3. If considering use despite warnings:

   • Must implement mandatory DVT prophylaxis
   • Target hemoglobin should NOT exceed 11 g/dL (higher targets increase cardiovascular risk) 1
   • Monitor closely for thrombotic events, hypertension, and cardiovascular complications

Common Pitfalls to Avoid

• Do not use Retacrit to achieve "normal" hemoglobin levels - targeting hemoglobin >11 g/dL increases serious cardiovascular risks without additional benefit 1
• Do not overlook the specific CABG surgery warning - this is explicitly mentioned in the FDA label as a high-risk scenario
• Do not use without concurrent DVT prophylaxis if administration is deemed necessary 1
• Do not assume the erythropoietic benefit outweighs thrombotic risk in the immediate postoperative period when inflammation and coagulation are already activated

Alternative Considerations

Given the significant contraindications and warnings, transfusion of packed red blood cells may be safer than Retacrit in the immediate post-cardiothoracic surgery period, particularly in CABG patients where the FDA has specifically identified increased mortality risk. The risk-benefit calculation heavily favors avoiding ESAs in this vulnerable population unless absolutely necessary and only after careful consideration of all contraindications and implementation of thromboprophylaxis.